Synthesis and in vitro biological evaluation of carbonyl group-containing inhibitors of vesicular acetylcholine transporter.
暂无分享,去创建一个
R. Mach | S. Efange | Z. Tu | S. Parsons | A. Khare | K. von Hohenberg
[1] R. Koeppe,et al. Positron emission tomography imaging of (2R,3R)-5-[(18)F]fluoroethoxybenzovesamicol in rat and monkey brain: a radioligand for the vesicular acetylcholine transporter. , 2009, Nuclear medicine and biology.
[2] R. Mach,et al. Synthesis and in vitro and in vivo evaluation of 18F-labeled positron emission tomography (PET) ligands for imaging the vesicular acetylcholine transporter. , 2009, Journal of medicinal chemistry.
[3] K. Ishiwata,et al. The potential of (−)‐o‐[11C]methylvesamicol for diagnosing cholinergic deficit dementia , 2008, Synapse.
[4] J. Seibyl,et al. Comparison of Noninvasive Quantification Methods of in Vivo Vesicular Acetylcholine Transporter Using [123I]-IBVM SPECT Imaging , 2008, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[5] J. Dartigues,et al. In vivo SPECT imaging of vesicular acetylcholine transporter using [123I]-IBVM in early Alzheimer's disease , 2008, NeuroImage.
[6] M. Scheunemann,et al. A new 18F-labeled fluoroacetylmorpholino derivative of vesamicol for neuroimaging of the vesicular acetylcholine transporter. , 2008, Nuclear medicine and biology.
[7] R. Mach,et al. Fluorine-18-labeled benzamide analogues for imaging the sigma2 receptor status of solid tumors with positron emission tomography. , 2007, Journal of medicinal chemistry.
[8] A. Terry,et al. Time-Dependent Cognitive Deficits Associated with First and Second Generation Antipsychotics: Cholinergic Dysregulation as a Potential Mechanism , 2007, Journal of Pharmacology and Experimental Therapeutics.
[9] C. Guatimosim,et al. Mice Deficient for the Vesicular Acetylcholine Transporter Are Myasthenic and Have Deficits in Object and Social Recognition , 2006, Neuron.
[10] H. Soreq,et al. Virtues and woes of AChE alternative splicing in stress-related neuropathologies , 2006, Trends in Neurosciences.
[11] R. Mach,et al. Carbon-11 labeled σ2 receptor ligands for imaging breast cancer , 2005 .
[12] R. Mach,et al. [3H]N-[4-(3,4-dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)butyl]-2-methoxy-5-methylbenzamide: a novel sigma-2 receptor probe. , 2005, European journal of pharmacology.
[13] S. Kish,et al. Brain vesicular acetylcholine transporter in human users of drugs of abuse , 2004, Synapse.
[14] A. Graybiel,et al. Evidence for a deficit in cholinergic interneurons in the striatum in schizophrenia , 1999, Neuroscience.
[15] R. Mach,et al. Hydroxylated decahydroquinolines as ligands for the vesicular acetylcholine transporter: synthesis and biological evaluation. , 1999, Journal of medicinal chemistry.
[16] T. Kitamoto,et al. Structure and Organization of the DrosophilaCholinergic Locus* , 1998, The Journal of Biological Chemistry.
[17] R. Mach,et al. N-hydroxyalkyl derivatives of 3 beta-phenyltropane and 1-methylspiro[1H-indoline-3,4'-piperidine]: vesamicol analogues with affinity for monoamine transporters. , 1997, Journal of medicinal chemistry.
[18] J. Dedman,et al. Molecular characterization of the mouse vesicular acetylcholine transporter gene , 1997, Neuroreport.
[19] K. Ajiki,et al. Localization of two cholinergic markers, choline acetyltransferase and vesicular acetylcholine transporter in the central nervous system of the rat: in situ hybridization histochemistry and immunohistochemistry , 1997, Journal of Chemical Neuroanatomy.
[20] D. Holtzman,et al. Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[21] S. Minoshima,et al. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease , 1996, Annals of neurology.
[22] D. Kuhl,et al. Vesamicol receptor mapping of brain cholinergic neurons with radioiodine-labeled positional isomers of benzovesamicol. , 1996, Journal of medicinal chemistry.
[23] M. Schäfer,et al. Visualization of the vesicular acetylcholine transporter in cholinergic nerve terminals and its targeting to a specific population of small synaptic vesicles. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[24] H. Yi,et al. Expression of the putative vesicular acetylcholine transporter in rat brain and localization in cholinergic synaptic vesicles , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[25] T. Bonner,et al. Molecular biology of the vesicular ACh transporter , 1995, Trends in Neurosciences.
[26] R. Mach,et al. Vesamicol analogues as sigma ligands. Molecular determinants of selectivity at the vesamicol receptor. , 1995, Biochemical pharmacology.
[27] R. Edwards,et al. Molecular cloning of a putative vesicular transporter for acetylcholine. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[28] T. Bonner,et al. Functional identification of a vesicular acetylcholine transporter and its expression from a "cholinergic" gene locus. , 1994, The Journal of biological chemistry.
[29] C. Foulon,et al. Spirovesamicols: conformationally restricted analogs of 2-(4-phenylpiperidino)cyclohexanol (vesamicol, AH5183) as potential modulators of presynaptic cholinergic function. , 1994, Journal of medicinal chemistry.
[30] N Butters,et al. Clinical correlates of cortical and nucleus basalis pathology in Alzheimer dementia. , 1994, Archives of neurology.
[31] T. Bonner,et al. Cloning and expression of the vesamicol binding protein from the marine ray Torpedo , 1994, FEBS letters.
[32] G. Rogers,et al. Kinetic and equilibrium characterization of vesamicol receptor-ligand complexes with picomolar dissociation constants. , 1993, Molecular pharmacology.
[33] P. Dudchenko,et al. Interactions between the effects of basal forebrain lesions and chronic treatment with MDL 26,479 on learning and markers of cholinergic transmission , 1993, Brain Research.
[34] S. Efange,et al. Nonsymmetrical bipiperidyls as inhibitors of vesicular acetylcholine storage. , 1993, Journal of medicinal chemistry.
[35] S. Parsons,et al. The pharmacology of vesamicol: an inhibitor of the vesicular acetylcholine transporter. , 1992, General pharmacology.
[36] B. E. Evans,et al. Orally active, nonpeptide oxytocin antagonists. , 1992, Journal of medicinal chemistry.
[37] B Carragher,et al. Three-Dimensional Analysis of the Relationship Between Synaptic Pathology and Neuropil Threads in Alzheimer Disease , 1992, Journal of neuropathology and experimental neurology.
[38] E. Masliah,et al. Localization of amyloid precursor protein in GAP43-immunoreactive aberrant sprouting neurites in Alzheimer's disease , 1992, Brain Research.
[39] D. Salmon,et al. Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment , 1991, Annals of neurology.
[40] I. G. Marshall,et al. α-Adrenoceptor blocking properties of vesamicol , 1991 .
[41] S. Efange,et al. Acyclic analogues of 2-(4-phenylpiperidino)cyclohexanol (vesamicol): conformationally mobile inhibitors of vesicular acetylcholine transport. , 1991, Journal of medicinal chemistry.
[42] Y. Agid,et al. Choline acetyltransferase activity and [ 3H]vesamicol binding in the temporal cortex of patients with Alzheimer's disease, Parkinson's disease, and rats with basal forebrain lesions , 1990, Neuroscience.
[43] S. Kish,et al. [3H]Vesamicol binding in human brain cholinergic deficiency disorders , 1990, Neuroscience Letters.
[44] S. DeKosky,et al. Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity , 1990, Annals of neurology.
[45] Stephen W. Scheff,et al. Quantitative assessment of cortical synaptic density in Alzheimer's disease , 1990, Neurobiology of Aging.
[46] G. Rogers,et al. Synthesis, in vitro acetylcholine-storage-blocking activities, and biological properties of derivatives and analogues of trans-2-(4-phenylpiperidino)cyclohexanol (vesamicol). , 1989, Journal of medicinal chemistry.
[47] S. Snyder,et al. Structural determinants of sigma receptor affinity. , 1987, Molecular pharmacology.
[48] P. Davies,et al. Recent advances in the neurochemistry of Alzheimer's disease. , 1987, The Journal of clinical psychiatry.
[49] C. Altar,et al. Quantitative autoradiography of brain binding sites for the vesicular acetylcholine transport blocker 2-(4-phenylpiperidino)cyclohexanol (AH5183). , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[50] I. G. Marshall,et al. Studies on the blocking action of 2‐(4‐phenyl piperidino) cyclohexanol (AH5183) , 1970, British journal of pharmacology.
[51] M. Scheunemann,et al. Neuroimaging of the vesicular acetylcholine transporter by a novel 4-[18F]fluoro-benzoyl derivative of 7-hydroxy-6-(4-phenyl-piperidin-1-yl)-octahydro-benzo[1,4]oxazines. , 2009, Nuclear medicine and biology.
[52] M. Schäfer,et al. Distribution of the vesicular acetylcholine transporter (VAChT) in the central and peripheral nervous systems of the rat , 2007, Journal of Molecular Neuroscience.
[53] M. Schäfer,et al. Human and monkey cholinergic neurons visualized in paraffin-embedded tissues by immunoreactivity for VAChT, the vesicular acetylcholine transporter , 2007, Journal of Molecular Neuroscience.
[54] S. Parsons,et al. Acetylcholine transport, storage, and release. , 1993, International review of neurobiology.
[55] C. Altar,et al. [3H]vesamicol binding in brain: Autoradiographic distribution, pharmacology, and effects of cholinergic lesions , 1988, Synapse.